Pharmaceuticals News and Research

RSS

Extensive study of natalizumab

Scientists have completed an extensive study of more than 3,000 patients who received a promising anti-inflammatory drug, natalizumab, that was linked to three cases of a serious brain infection in large clinical trials halted in early 2005.

7 Mar 2006

Data from Novogen inflammatory bowel disease drug Phase I clinical trial shows promise

A recently completed Phase 1 clinical trial of an investigational drug to treat inflammatory bowel disease has demonstrated rapid absorption indicating potential for development as an oral therapy.

6 Mar 2006

Next-generation drug development: risky and costly, but worth it

Generic drugs, which drive a $40 billion dollar generics industry expected to hit $60 billion by 2007, account for 53% of all prescriptions filled in the United States today.

6 Mar 2006

FDA grants priority review for Revlimid

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review designation to its Supplemental New Drug Application (sNDA) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory multiple myeloma.

6 Mar 2006

Study shows new atopic dermatitis therapy significantly delays onset of flares

Stiefel Laboratories, the world's largest independent pharmaceutical company specializing in dermatology, announced that a recent study shows MimyX Cream extends the remission period of atopic dermatitis (AD) by 48 percent when used in conjunction with an emollient compared to emollient alone.

6 Mar 2006

Orthopaedic medical device technologies that offer greater clinical benefits expected to succeed

Current users of medical device technologies for orthopaedic applications seek systems that offer maximum comfort while requiring minimum physical supervision. This is driving the market to continuously evolve technologies that use radically different approaches or make significant improvements to existing products.

6 Mar 2006

Trials on MS drug Tysabri renews hope for sufferers

According to the results of two new trials the multiple sclerosis (MS) drug Tysabri significantly reduces the progression of the disease.

5 Mar 2006

Rhodium quinones promise better drugs

By combining a common organic compound with a rare metal, a team of Brown University chemists has created a new class of molecules that have potentially important applications for the pharmaceutical, chemical and energy industries.

1 Mar 2006

FDA shields drug companies from lawsuits

Last month, the FDA revealed its latest protective policy for drug companies in a statement that said people who believe they have been injured by drugs approved by the FDA should not be allowed to sue drug companies in state courts.

1 Mar 2006

Crystal meth the new drug pandemic

According to a U.N. narcotics watchdog the synthetic drug methamphetamine is a bigger problem in the United States and other countries than either heroin or cocaine.

1 Mar 2006

Clinical trial of new Bionovo menopause drug moves forward

Today, millions of women suffer from often-harsh symptoms of menopause such as hot flashes and night sweats -- and relief is nowhere to be found.

27 Feb 2006

Ginkgo biloba reduces aggressive cancer risk in animal experiments

Researchers at Georgetown University Medical Center say they now have a clearer picture of how an extract from the leaves of the Ginkgo biloba tree reduces the risk of aggressive cancer in animal experiments.

27 Feb 2006

Teatments based on behaviour could reduce prescription drug use

New psychological treatments - behavioural medicine - could significantly reduce the need for drug treatments for some conditions, cutting health system costs says an editorial in this week's British Medical Journal.

27 Feb 2006

Chromium industry withheld data from the U.S. government

According to a new report scientists funded by the chromium industry withheld key data from the U.S. government which called for a strict standard to be imposed regarding workplace exposure to hexavalent chromium.

27 Feb 2006

Takeda wins patent infringement case

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc. have announced that Takeda's intellectual property rights have been successfully asserted against generic manufacturers seeking to challenge Takeda's patent rights to ACTOS (pioglitazone HCl).

24 Feb 2006